Harold Kleanthous

This inventor holds 16 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Sanofi Pasteur Biologics, LLC, Sanofi Pasteur Inc., Oregon Health & Science University. Active years: 1998-2024.

USPTO Granted Patents = 16 (Patent Applications = 5)

% Patents Active = 43.8

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 31(Granted Patents)

Location History:

Allston, MA (US) (1998)
Westford, MA (US) (2003 - 2016)
Chelmsford, MA (US) (2018 - 2023)

Company Filing History:

8 out of 24

Sanofi Pasteur Biologics, LLC

Oregon Health & Science University

where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12116402 - Antibodies against clostridium difficile toxins and methods of using the same (2024-10-15),

2. 11576964 - Methods of generating broadly protective vaccine compositions comprising hemagglutinin (2023-02-14),

3. 11220537 - Antibodies againsttoxins and methods of using the same (2022-01-11),

4. 10925957 - Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza (2021-02-23),

5. 10548965 - Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza (2020-02-04),

6. 10220086 - Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza (2019-03-05),

7. 10160797 - [object Object] (2018-12-25),

8. 9381237 - Neutralizing immunogen (NimIV) of rhinovirus and its uses for vaccine applications (2016-07-05),

9. 9228203 - Recombinant bicistronic flavivirus vectors (2016-01-05),

10. 9217158 - Replication-defective flavivirus vaccines and vaccine vectors (2015-12-22),

11. 8815564 - Replication-defective flavivirus vaccines and vaccine vectors (2014-08-26),

12. 8652486 - Neutralizing immunogen (NimIV) of rhinovirus and its use for vaccine applications (2014-02-18),

13. 8486417 - [object Object] (2013-07-16),

14. 7569383 - Chimeric flavivirus vectors (2009-08-04),

15. 6585975 - Use of Salmonella vectors for vaccination against helicobacter infection (2003-07-01),

Title: Harold Kleanthous: Innovator in Antibody and Vaccine Development

Introduction

Harold Kleanthous is a prominent inventor based in Westford, MA (US), known for his significant contributions to the fields of immunology and vaccine development. With a total of 16 patents, he has made remarkable strides in creating innovative solutions for infectious diseases.

Latest Patents

Among his latest patents, Kleanthous has developed monoclonal antibodies that target clostridium difficile toxins. These antibodies are designed to detect or treat infections and associated diseases effectively. Additionally, he has worked on methods for generating broadly protective vaccine compositions that comprise hemagglutinin. This approach utilizes a cluster-based consensus method to create recombinant hemagglutinin polypeptides, which are essential for developing effective influenza vaccine compositions.

Career Highlights

Throughout his career, Kleanthous has been associated with notable companies such as Sanofi Pasteur Biologics, LLC and Sanofi Pasteur Inc. His work in these organizations has significantly advanced the understanding and treatment of infectious diseases.

Collaborations

Kleanthous has collaborated with esteemed colleagues, including Stephen F Anderson and Natalie Anosova, to further enhance his research and development efforts.

Conclusion

Harold Kleanthous stands out as an influential inventor in the realm of antibody and vaccine research. His innovative patents and collaborations continue to impact the field of immunology positively.